News Search Results
Apr 21, 2026, 16:15 ET BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
product development."We're pleased to receive this recognition from INTERPHEX, one of the industry's leading forums for pharmaceutical and biotechnology innovation," said Roderick de Greef, CEO of BioLife Solutions. "This award is meaningful validation that CryoCase addresses a real need in the market.
More news about: BioLife Solutions, Inc.
Apr 21, 2026, 13:36 ET CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics
AI-powered technology to identify and place exceptional C-suite and senior leadership talent with speed and precision. The firm serves clients across biotechnology, biopharma, diagnostics, medical technology, and health technology sectors. Learn more at collectivemindsllc.com.About Genova DiagnosticsGenova
More news about: CollectiveMinds LLC
Apr 21, 2026, 12:15 ET TOSLA and Geltor Launch the First Vegan Signaling Collagen Liquid Supplement, Powered by PrimaColl®, a Type 21 Signaling Collagen
Signaling Collagen Shot in partnership with biotechnology pioneer,
More news about: TOSLA
Apr 21, 2026, 11:11 ET Alcami to Acquire Contract Packaging Organization Tjoapack
www.alcami.com.About TjoapackTjoapack is a global contract packaging organization (CPO) serving the pharmaceutical and biotechnology industries, with more than 35 years of experience in regulated pharmaceutical packaging. Founded in 1989 and headquartered in The Netherlands, the
More news about: Alcami
Apr 21, 2026, 09:36 ET L-Nutra CEO Dr. Joseph Antoun Named LA Times 'Life Sciences Visionary' for Pioneering Longevity as a Medical Discipline
and CEO, Joseph Antoun, MD, PhD, has been named a 2026 Life Sciences Visionary by LA Times Studios, recognizing leaders driving innovation across biotechnology and healthcare.
More news about: L-Nutra Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for
More news about: Northwest Biotherapeutics, Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for
More news about: Northwest Biotherapeutics, Inc.
Apr 21, 2026, 09:11 ET ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
therapeutic response, and development of next-generation therapies. The platform will create a shared infrastructure for academic investigators, biotechnology companies, and clinical researchers to interrogate disease mechanisms, predict drug response in silico, validate targets, and develop tailored therapeutic
More news about: ReviR Therapeutics
Apr 21, 2026, 09:05 ET Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scientific oversight and
More news about: Insilico Medicine
Apr 21, 2026, 08:46 ET BiomEdit Secures Foundational Patents for Engineered Probiotic Platform Positioned to Redefine Animal Health
GREENFIELD, Ind., April 21, 2026 /PRNewswire/ -- BiomEdit, an animal health biotechnology company, today announced the issuance of foundational patents covering its engineered probiotic delivery platform. These patents support and directly
More news about: BiomEdit
Apr 21, 2026, 08:30 ET HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
NHP centers in Guangxi and Suzhou, and a state-of-the-art analysis center and rodent facility in Suzhou, serving over 1000 pharmaceutical and biotechnology clients, HKeybio is committed to providing the global biopharmaceutical industry with the most clinically relevant disease models.Through
More news about: HKeyBio
Apr 21, 2026, 08:03 ET USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS™ CDR-Scanning
genera using structure-based claims supported by comprehensive experimental data, based on Integral Molecular's 2025 publication in Nature Biotechnology2. The allowance comes in the wake of the 2023 U.S. Supreme Court ruling in Amgen Inc. v. Sanofi, which emphasized that genus claims must be
More news about: Integral Molecular
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
https://www.pulmatrix.com/pipeline.html.About Eos SENOLYTIX, Inc.Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos's
More news about: Pulmatrix Inc.
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
well as the novel biologic ZYMFENTRA® (infliximab-dyyb).Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Apr 21, 2026, 06:30 ET Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the launch of Serif Biomedicines, a biotechnology company pioneering Modified DNA as a new class of medicines. Modified DNA brings together the best features of mRNA and gene therapy, while mitigating
More news about: Flagship Pioneering
Apr 21, 2026, 06:00 ET Danaher Reports First Quarter 2026 Results
D Impairment charges related to a facility in the Biotechnology segment recorded in the three-month period ended March 28, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).
More news about: Danaher Corporation
Apr 20, 2026, 22:34 ET Quality Executive Partners, Inc.® Announces Exclusive Partnership with Vi'eNnI® Training and Consulting LLP to Accelerate Workforce Development in India's Huge Pharmaceutical Sector with Virtuosi®
sustainable compliance. Known for its practical, implementation-focused approach, Vi'eNnI® enables pharmaceutical and biotechnology companies to translate training into measurable improvements on the shop floor, supporting continuous improvement and long-term capability development
More news about: Quality Executive Partners, Inc.
Apr 20, 2026, 16:01 ET Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
More news about: Nektar Therapeutics
Apr 20, 2026, 15:36 ET AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies
significant business activities in, or significant exposure to, the psychedelics industry including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that are part of the supply chain for psychedelics. Psychedelics
More news about: AdvisorShares
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with
More news about: Abogen
Apr 20, 2026, 09:30 ET Atlas Data Storage Selected to Present at TSMC Technology Symposium
Innovation Zone," said Siraj Nour ElAhmadi , Atlas COO. "This recognition reflects Atlas leadership in the convergence of semiconductor scaling and biotechnology. Our platform leverages advanced CMOS designs to enable the massive parallelization and controls of a molecular substrate unlocking new categories
More news about: Atlas Data Storage
Apr 20, 2026, 09:00 ET Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 20, 2026 /PRNewswire/ -- Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA1-driven
More news about: Congruence Therapeutics
Apr 20, 2026, 09:00 ET Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.Kelonia has developed
More news about: Eli Lilly and Company
Apr 20, 2026, 09:00 ET Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
[email protected] EclipsebioEclipsebio is a private biotechnology company headquartered in San Diego that combines AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug
More news about: Eclipsebio